-
-
-
-
-
-
-
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
-
-
-
-
-
-
-
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
-
-
-
-
-
-
-
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
-
-
-
-
-
-
-
Ipsen: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 27 May 2021 (17th resolution
-
-
-
-
-
-
-
Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results
-
-
-
-
-
-
-
Ipsen Provides Update on Palovarotene Clinical Programs
-
-
-
-
-
-
-
New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting
-
1,171,128 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

